Watanabe Takuya, Okuda Katsuhiro, Murase Takayuki, Moriyama Satoru, Haneda Hiroshi, Kawano Osamu, Yokota Keisuke, Sakane Tadashi, Oda Risa, Inagaki Hiroshi, Nakanishi Ryoichi
Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Oncotarget. 2018 Apr 17;9(29):20769-20780. doi: 10.18632/oncotarget.25100.
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM. We studied the PD-L1 expression using four immunohistochemical assays (SP142, SP263, 28-8 and 22C3) in 32 MPM patients. The PD-L1 expression in tumor cells and immune cells was evaluated to clarify the rate of PD-L1 expression and the concordance among the four assays in MPM. The positivity rate of PD-L1 expression was 53.1% for SP142, 28.1% for SP263, 53.1% for 28-8, and 56.3% for 22C3. Nine cases were positive and 10 were negative for all assays. Discordance among the four assays was found in 13 cases. The concordance rates between SP142 and 22C3 and between 28-8 and 22C3 were the highest (84.4%). The concordance rates between SP263 and the other three assays were low (71.9% to 75.0%). The PD-L1 expression in MPM was almost equivalent for three of the assays. Given the cut-off values set in our study, these findings suggested that these assays, except for SP263, can be used for accurate PD-L1 immunostaining in MPM.
靶向PD-1/PD-L1通路的免疫检查点抑制剂（ICIs）有望成为应对未来恶性胸膜间皮瘤（MPM）患者数量增加的一种新型疗法。然而，作为ICIs反应预测指标的PD-L1表达情况在MPM中尚不清楚。我们使用四种免疫组织化学检测方法（SP142、SP263、28-8和22C3）对32例MPM患者的PD-L1表达进行了研究。评估肿瘤细胞和免疫细胞中的PD-L1表达，以明确MPM中PD-L1表达率以及四种检测方法之间的一致性。SP142检测的PD-L1表达阳性率为53.1%，SP263为28.1%，28-8为53.1%，22C3为56.3%。所有检测方法均为阳性的有9例，均为阴性的有10例。在13例中发现四种检测方法之间存在不一致。SP142与22C3之间以及28-8与22C3之间的一致性率最高（84.4%）。SP263与其他三种检测方法之间的一致性率较低（71.9%至75.0%）。三种检测方法检测的MPM中的PD-L1表达几乎相当。根据我们研究中设定的临界值，这些结果表明，除SP263外，这些检测方法可用于MPM中准确的PD-L1免疫染色。
J Cancer Res Clin Oncol. 2024-1-28
Nat Rev Clin Oncol. 2022-9
Immunooncol Technol. 2019-9-16
Transl Lung Cancer Res. 2021-6
Front Oncol. 2021-6-23
J Thorac Oncol. 2017-2-28
Lung Cancer. 2016-12-12
N Engl J Med. 2016-10-8
N Engl J Med. 2016-11-10
Zotero 插件
